Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.15 on revenue of $533.8M. Analysts polled by Investing.com anticipated EPS of $0.0257 on revenue of $520.35M.
Biomarin Pharma shares are up 0.06% from the beginning of the year and are trading at $88.21 , down-from-52-week-high.They are outperforming the Nasdaq which is down 19.03% from the start of the year.
Biomarin Pharma shares lost 0.21% in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar